Neurofibromatoses Type I (Von Recklinghausen's Disease) - Pipeline Review, H1 2017

  • ID: 4318713
  • Report
  • 49 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Array BioPharma Inc
  • AstraZeneca Plc
  • Celldex Therapeutics Inc
  • MORE
Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2017, provides an overview of the Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline landscape.

Neurofibromatosis type 1 (NF1), also called von Recklinghausen's disease, is a rare genetic disorder characterized by the development of multiple noncancerous (benign) tumors of nerves and skin (neurofibromas). This is transmitted on chromosome 17 and is caused by mutation of the NF1 gene. Symptoms include liver enlargement, glioma, Lisch nodules and pheochromocytoma. Treatment includes pain medications, surgery, chemotherapy and radiation therapy.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 1 and 2 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders)
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Neurofibromatoses Type I (Von Recklinghausen’s Disease) (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Array BioPharma Inc
  • AstraZeneca Plc
  • Celldex Therapeutics Inc
  • MORE
  1. Introduction
  2. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Overview
  3. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Companies Involved in Therapeutics Development
  15. Alexion Pharmaceuticals Inc
  16. Array BioPharma Inc
  17. AstraZeneca Plc
  18. Celldex Therapeutics Inc
  19. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Drug Profiles
  20. asfotase alfa - Drug Profile
  21. Product Description
  22. Mechanism Of Action
  23. R&D Progress
  24. binimetinib - Drug Profile
  25. Product Description
  26. Mechanism Of Action
  27. R&D Progress
  28. CDX-0158 - Drug Profile
  29. Product Description
  30. Mechanism Of Action
  31. R&D Progress
  32. selumetinib sulfate - Drug Profile
  33. Product Description
  34. Mechanism Of Action
  35. R&D Progress
  36. Small Molecules for Neurofibromatoses Type I - Drug Profile
  37. Product Description
  38. Mechanism Of Action
  39. R&D Progress
  40. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects
  41. Appendix
  42. Methodology
  43. Coverage
  44. Secondary Research
  45. Primary Research
  46. Expert Panel Validation
  47. Contact Us
  48. Disclaimer
List of Tables
  1. Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products under Development by Universities/Institutes, H1
  4. Products under Development by Companies, H1
  5. Products under Development by Universities/Institutes, H1
  6. Number of Products by Stage and Target, H1
  7. Number of Products by Stage and Mechanism of Action, H1
  8. Number of Products by Stage and Route of Administration, H1
  9. Number of Products by Stage and Molecule Type, H1
  10. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Alexion Pharmaceuticals Inc, H1
  11. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Array BioPharma Inc, H1
  12. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by AstraZeneca Plc, H1
  13. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Pipeline by Celldex Therapeutics Inc, H1
  14. Neurofibromatoses Type I (Von Recklinghausen’s Disease) - Dormant Projects, H1
List of Figures
  1. Number of Products under Development for Neurofibromatoses Type I (Von Recklinghausen’s Disease), H1
  2. Number of Products under Development by Companies, H1
  3. Number of Products by Targets, H1
  4. Number of Products by Stage and Targets, H1
  5. Number of Products by Mechanism of Actions, H1
  6. Number of Products by Stage and Mechanism of Actions, H1
  7. Number of Products by Routes of Administration, H1
  8. Number of Products by Stage and Routes of Administration, H1
  9. Number of Products by Molecule Types, H1
  10. Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alexion Pharmaceuticals Inc
  • Array BioPharma Inc
  • AstraZeneca Plc
  • Celldex Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll